0001104659-23-122909.txt : 20231201 0001104659-23-122909.hdr.sgml : 20231201 20231201172544 ACCESSION NUMBER: 0001104659-23-122909 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231025 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 231460568 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 tm2330328d1_8k.htm FORM 8-K
false 0001585608 0001585608 2023-10-25 2023-10-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 25, 2023 

 

 

 

JAGUAR HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36714 46-2956775
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

200 Pine Street, Suite 400

San Francisco, California

94104
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (415) 371-8300 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Market

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Office Lease

 

As previously disclosed, on April 6, 2021, Jaguar Health, Inc. (the “Company”) entered into an Office Lease Agreement (the “Lease”) with M & E, LLC, a California Limited Liability Company (“Landlord”), to lease approximately 10,526 square feet of office space for two suites located at 200 Pine Street, San Francisco, California 94104 (the “Premises”). The original term of the Lease provided that the lease began on September 1, 2021 and would expire on August 31, 2024. On December 24, 2021, the Company entered into the First Amendment to the Lease (the “First Amendment”), which, among other things, modified the Lease to begin on December 22, 2021 and expire on February 28, 2025.

 

On October 25, 2023, the Company entered into a Second Amendment to the Lease (the “Second Amendment”), which, among other things, modified the date of expiration for one of the suites covered under the Lease from February 28, 2025 to August 31, 2030.

 

Pursuant to the Second Amendment, the base rent under the Lease was modified to read as follows:

 

  SUITE 400   SUITE 600    
MONTHLY PERIOD  Monthly
Basic Rental
   Monthly
Basic Rental
   TOTAL MONTHLY
BASIC RENTAL
 
9/1/2023 – 2/29/2024  $17,587.33   $21,683.56   $39,270.89 
3/1/2024 – 8/31/2024  $17,587.33   $22,334.07   $39,921.40 
9/1/2024 – 2/28/2025  $18,114.95   $22,334.07   $40,449.02 
3/1/2025 – 8/31/2025  $18,114.95        $18,114.95 
9/1/2025 – 8/31/2025  $18,658.40        $18,658.40 
9/1/2026 – 8/31/2025  $19,218.15        $19,218.15 
9/1/2027 – 8/31/2025  $19,794.70        $19,794.70 
9/1/2028 – 8/31/2025  $20,388.54        $20,388.54 
9/1/2029 – 8/31/2025  $21,000.20        $21,000.20 

  

The description of the First Amendment and the Second Amendment contained in this Current Report on Form 8-K do not purport to be complete and are qualified in their entirety by reference to the copy of the First Amendment and the Second Amendment filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit
No.
  Description
     
10.1   First Amendment to 200 Pine Street Office Lease, dated December 24, 2021, between Jaguar Health, Inc. and M & E, LLC.
     
10.2   Second Amendment to 200 Pine Street Office Lease, dated October 25, 2023, between Jaguar Health, Inc. and M & E, LLC.
     
 104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JAGUAR HEALTH, INC.
   
   
  By: /s/ Lisa A. Conte
    Name: Lisa A. Conte
    Title: President and Chief Executive Officer

 

Date: December 1, 2023

 

 

 

EX-10.1 2 tm2330328d1_10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

FIRST AMENDMENT TO LEASE

 

THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of December 24, 2021 (the “Effective Date”), by and between M & E, LLC., a California limited liability corporation (“Landlord”) and Jaguar Health, Inc., a Delaware corporation (“Tenant”), with reference to the following facts:

 

A.            Landlord and Tenant are parties to that certain Lease dated as of March 25, 2021, (the “Lease”), pursuant to which Landlord leases to Tenant space (the “Premises”) containing approximately 10,526 rentable square feet (“RSF”) described as Suite 400 and 600 on the fourth and sixth floors of the building located at 200 Pine Street, San Francisco, California (the “Building”).

 

B.            Due to no fault of the Tenant, on or about July 17, 2021, the Building suffered from substantial water damage due to water intrusion emanating from the roof of the building and all floors in the building suffered significant damage (the “Water Damage”).

 

C.            The Lease by its terms was schedule to commence on September 1, 2021. However, due to the Water Damage Tenant was unable to occupy Suite 600 of the Building until late December 2021.

 

D.            the parties, therefore, desire to modify the Commencement Date of the Lease, among other terms and conditions outlined herein.

 

NOW, THEREFORE, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:

 

1.            Commencement Date. The Commencement Date is hereby modified to be December 22, 2021.

 

2.            Rent Commencement Date. The Rent Commencement Date is hereby modified to be March 1, 2022.

 

3.            Monthly Basic Rental.

 

(a)            Generally. During the Term, Tenant will pay as Monthly Basic Rental for the Premises the following:

 

Period  Annual Rate
Per RSF
   Monthly Basic
Rental
 
3/1/22 — 2/28/23  $48.00   $42,104.00 
3/1/23 — 2/28/24  $49.44   $43,367.12 
3/1/24 — 2/28/25  $50.92   $44,668.13 

 

 

 

 

All such Monthly Basic Rental shall be payable by Tenant in accordance with the terms of the Lease.

 

(b)            Fourth (4th) Floor Rent prior to the Commencement Date. It is agreed and acknowledged that Tenant’s rent for the period of September 1, 2021, until February 28, 2022, shall be $21,052.00, until the Commencement Date.

 

4.            Condition of Premises. Tenant is in possession of the Premises and will accept the Premises in its “as is” condition on the Effective Date without any agreements, representations, understandings or obligations on the part of Landlord to (i) perform any alterations, additions, repairs or improvements, (ii) fund or otherwise pay for any alterations, additions, repairs or improvements to the Premises, or (iii) grant Tenant any free rent, concessions, credits or contributions of money with respect to the Premises, except for the following:

 

·The sixth (6th) floor doors that were replaced/repaired by Landlord shall have their doorknobs re installed

 

·The door on the first office off the sixth floor lobby needs to be adjusted, it sticks

 

·Suite 600 and exterior callbox Tenant signage shall read “Jaguar Animal Health”

 

·Landlord shall reimburse Tenant for IT work, not to exceed $900

 

·Landlord shall complete necessary repairs to restore the fourth (461) floor restrooms to good working order and repair, work to be completed no later than January 10, 2022

 

·Landlord shall provide Tenant with 20 keys to Suite 600 and 20 keys to the stairwell door (if keyed differently)

 

·Landlord shall repair or replace damaged ceiling tiles on the fourth floor

 

·Landlord shall replace baseboard on damaged walls on the fourth floor

 

·Landlord shall replace damaged flooring on the fourth floor

 

5.            Miscellaneous.

 

(a)            This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements.

 

(b)            Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.

 

 

 

 

(c)            In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.

 

(d)            Submission of this Amendment by Landlord is not an offer to enter into this Amendment. Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.

 

(e)             Capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.

 

(f)             Each signatory of this Amendment represents hereby that he or she has the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.

 

(g)            This Amendment may be executed in multiple counterparts each of which is deemed an original but together constitute one and the same instrument. This Amendment may be executed in so-called “pdf’ format and each party has the right to rely upon a pdf counterpart of this Amendment signed by the other party to the same extent as if such party had received an original counterpart.

 

[SIGNATURES ARE ON FOLLOWING PAGE]

 

 

 

 

IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Amendment as of the Effective Date.

 

LANDLORD:

 

M & E, LLC.,
a California limited liability corporation

 

By: /s/ Elsie Sze  
Print Name: Elsie Sze  
Its: Director & CEO  

 

TENANT:

 

Jaguar Health, Inc.,
a Delaware corporation

 

By: /s/ Lisa Conte  
Print Name: Lisa Conte  
Its: CEO  

 

 

 

EX-10.2 3 tm2330328d1_10-2.htm EXHIBIT 10.2

 

Exhibit 10.2

 

SECOND AMENDMENT TO 200 PINE STREET OFFICE LEASE

 

This Second Amendment to 200 Pine Street Office Lease (“Second Amendment”) is made and entered into as of October 25, 2023 (“Effective Date”) by and between M & E, LLC, a California limited liability company (“Landlord”), and Jaguar Health, Inc. a Delaware corporation (“Tenant”). Landlord and Tenant are sometimes individually referred to as a “Party” and sometimes collectively referred to as “Parties.”

 

RECITALS

 

A.            Landlord owns the commercial mixed-use building located at 200 Pine Street, San Francisco, California (“Building”).

 

B.            Landlord and Tenant entered into the 200 Pine Street Office entered into as of March 15, 2021 (“Original Lease”) by which Landlord leased to Tenant that portion of the Building located on the fourth (4th) and sixth (6th) floors of the Building and known as Suite 400 and Suite 600, as depicted on Exhibit A to the Original Lease. Since the Original Lease was executed, the Building was remeasured so that the total Rentable Area of the Building is 10,992 RSF. In calculating the Monthly Basic Rental in the chart in Paragraph 7 of this Second Amendment,

 

(i)             For Suite 400 the Rentable Area of 5,735 square feet was used, as determined from the remeasurement of the Building; and

 

(ii)            For Suite 600, the Rentable Area of 5,263 square feet was used, as stated in the Original Lease The Monthly Basic Rental for Suite 600 was determined by taking 50% of the Monthly Basic Rental as indicated in the chart in Paragraph 3 of the First Amendment.

 

C.            The Parties entered into the First Amendment to Lease (“First Amendment”) as of December 24, 2021, which First Amendment modified the Commencement Date to be December 22, 2021, the Rent Commencement Date to be March 1, 2022, and the Expiration Date to be February 28, 2025.

 

D.            The Original Lease, as amended by the First Amendment and this Second Amendment, is referred to as the “Lease.”

 

E.            The Parties enter into this Second Amendment to accomplish the following:

 

(i)            Tenant’s occupancy of Suite 400 and Suite 600 will continue under the terms of the Original Lease as amended by the First Amendment and this Second Amendment;

 

(ii)            Tenant’s occupancy of Suite 600 will have an Expiration Date of February 28, 2025; and

 

(iii)           Tenant’s occupancy of Suite 400 will have a Commencement Date of September 1, 2023 and will have an Expiration Date of August 31, 2030.

 

 Page 1Second Amendment to 200 Pine Street Office Lease for Jaguar Health, Inc.

 

 

The Parties enter into this Second Amendment to amend following terms of the Original Lease.

 

TERMS OF SECOND AMENDMENT

 

1.            Recitals. The Recitals are incorporated into these Terms of Second Amendment as though each Recital was restated in full in these Terms of Second Amendment.

 

2.            Base Year: Section 1.2 of the Original Lease titled “Base Year” is deleted in its entirety and is replaced by the following:

 

The Base Year for Suite 600 is the calendar year of 2022.

 

The Base Year for Suite 400 is the calendar year of 2024.

 

3.            Expiration Date. Section 1.8 of the Original Lease titled “Expiration Date” as amended by the First Amendment is further amended to read as follows:

 

The Expiration Date for Suite 600 is February 28, 2025.

 

The Expiration Date for Suite 400 is August 31, 2030.

 

4.            Landlord’s Notice Address. Section 1.13 of the Original Lease titled “Landlord’s Notice Address” is deleted in its entirety and is replaced with the following:

 

1.13 Landlord’s Notice Address. c/o Transwestern, 123 Mission Street, Suite 1180, San Francisco, CA 94105, Attn. Somia Shaikh, Property Manager, Direct: 415.489.1750; email: Somia.Shaikh@transwestern.com, or such other address as Landlord shall designate from time to time.

 

5.            Tenant’s Proportionate Share. Section 1.21 of the Original Lease titled “Tenant’s Proportionate Share” is deleted in its entirety and is replaced by the following:

 

1.21 Tenant’s Proportionate Share: Suite 400 is 12.58% (5,735 RSF of Suite 400 / 45,591 RSF of the Building) and Suite 600 is 12.87% (50% of Tenant’s Proportionate Share of 25.74% as stated in Section 1.21 of the Original Lease).

 

6.            Option to Renew.

 

(a)            Section 3.3 of the Original Lease titled “Option to Renew” is amended by striking the words “three (3)” in the third line of the first paragraph in Section 3.3 and replacing these stricken words with “five (5).”

 

(b)            This Option to Renew shall apply separately to Tenant’s occupancy of only Suite 400 and not to Suite 600.

 

 Page 2Second Amendment to 200 Pine Street Office Lease for Jaguar Health, Inc.

 

 

7.            Monthly Basic Rental. The Monthly Basic Rental chart depicted in Paragraph 3 of the First Amendment is deleted in its entirety and is replaced by the following:

 

   SUITE 400   SUITE 600     
MONTHLY
PERIOD
  Annual
Rent/RSF
   Monthly
Basic Rental
   Annual
Rent/RSF
   Monthly
Basic
Rental
   TOTAL
MONTHLY
BASIC
RENTAL
 
9/1/2023 - 2/29/2024  $36.80   $17,587.33   $49.44   $21,683.56   $39,270.89 
3/1/2024 - 8/31/2024  $36.80   $17,587.33   $50.92   $22,334.07   $39,921.40 
9/1/2024 - 2/28/2025  $37.90   $18,114.95   $50.92   $22,334.07   $40,449.02 
3/1/2025 - 8/31/2025  $37.90   $18,114.95             $18,114.95 
9/1/2025 - 8/31/2026  $39.04   $18,658.40             $18,658.40 
9/1/2026 - 8/31/2027  $40.21   $19,218.15             $19,218.15 
9/1/2027 - 8/31/2028  $41.42   $19,794.70             $19,794.70 
9/1/2028 - 8/31/2029  $42.66   $20,388.54             $20,388.54 
9/1/2029 - 8/31/2030  $43.94   $21,000.20             $21,000.20 

 

8.            Rebate of Overpayment of Rent. As indicated in the above chart, Tenant overpaid the Monthly Basic Rental due for the month of September 2023 by Four Thousand Ninety-Six and 33/100 Dollars ($4,096.23) ($21,683.56 - $17,587.33). Landlord shall rebate this overpayment to Tenant or credit to this overpayment to Tenant’s account as Landlord elects. If Tenant overpays the Monthly Basic Rent for the month of October 2023, Landlord shall likewise rebate or credit this overpayment to Tenant or to Tenant’s account.

 

9.            Tenant Improvement Allowance.

 

(a)            Landlord shall provide Tenant with a Tenant improvement Allowance (“TIA”) of not to exceed Eighty-Six Thousand Twenty-Five Dollars ($86,025) ($15.00 per RSF x 5,735 RSF) beginning on March 1, 2025. Such TIA shall be reimbursed to Tenant for work completed in Suite 400 by Tenant or applied towards work completed by Landlord at Tenant’s request.

 

(b)            Within thirty (30) days after receipt of a request for disbursement from Tenant, Landlord shall disburse a portion of the TIA (up to the whole thereof) to Tenant for reimbursement to Tenant for Hard Costs actually paid by Tenant to contractors, subcontractors, materialmen and suppliers with respect to the Tenant Improvements theretofore completed or services performed or supplies furnished in connection therewith.

 

(c)            Landlord shall have no obligation to make any disbursement from the TIA if Tenant is in default of this Lease on the date of disbursement. Furthermore, Landlord’s obligation to make a disbursement from the TIA shall be subject to Landlord’s receipt of:

 

(i)            a request for such disbursement from Tenant signed by an authorized officer of Tenant;

 

(ii)           copies of paid invoices or other evidence reasonably satisfactory to Landlord of the Hard Costs actually paid or to be paid from proceeds by Tenant;

 

 Page 3Second Amendment to 200 Pine Street Office Lease for Jaguar Health, Inc.

 

 

(iii)          copies of all contracts, work orders, change orders and other materials relating to the work or materials which is the subject of the requested disbursement;

 

(iv)         a certificate of Tenant’s independent licensed architect stating, in his opinion, that the Tenant Improvements were performed in a good and workmanlike manner and substantially in accordance with the final detailed plans and specifications for such Tenant Improvements, as approved by Landlord;

 

(v)          no lien on account of work done for or materials furnished to Tenant or any of its contractors or subcontractors shall have been filed against any of the Property and not have been paid or bonded and, in either event, discharged of record; and

 

(vi)         lien waivers from the general contractor and all subcontractors and materialmen involved in the Tenant Improvements and any other work performed on the Premises.

 

(d)            In no event shall the aggregate amount paid by Landlord to Tenant under this Section exceed the amount of the TIA. It is expressly understood and agreed that Tenant shall complete, at its sole cost and expense, the Tenant Improvements, whether or not the TIA is sufficient to fund such completion. Any costs to complete the Tenant Improvements in excess of the TIA shall be the sole responsibility and obligation of Tenant.

 

(e)            All Tenant Improvements shall comply with the applicable terms of the Lease, including, but not limited to, Section 13 of the Original Lease titled “Alterations.”

 

10.            Security Deposit. Pursuant to the Original Lease, Landlord currently is holding a cash Security Deposit in the amount of Forty-Four Thousand Six Hundred Sixty-Eight and 13/100 Dollars ($44,668.13) which Landlord will continue to hold throughout the Term of this Lease. No portion of the Security Deposit shall be returned to Tenant at the end of the Term of the Lease for Suite 600.

 

11.            Brokerage Commission. Upon full execution of a Lease Amendment between Landlord and Tenant, Tenant’s representative, Recreate (“Tenant’s Broker”) shall earn and be due a commission , in an amount equal to $3.00 per RSF per year of the Lease Term not to exceed $15.00 per RSF commissions due for any partial Lease years shall be prorated. Such commission shall be paid 50% no later than January 31, 2024 and 50% no later than March 31, 2025 provided Tenant is not in default of the Lease at the time.

 

12.            Lease Remains in Effect. Except as amended by this Second Amendment, the terms of the Original Lease, as previously amended by the First Amendment, remain in effect.

 

13.            Conflict in Terms. If there is any conflict between the terms of this Second Amendment and the terms of the Original Lease, as amended by the First Amendment, the terms of this Second Amendment shall control.

 

14.            Reliance on Counsel. In entering into this Second Amendment, each Party has had the opportunity to rely upon the advice of its attorney or its consultants and has not relied upon any representation of law or fact by the other Party. It is further acknowledged by each Party that the Party executing this Second Amendment:

 

 Page 4Second Amendment to 200 Pine Street Office Lease for Jaguar Health, Inc.

 

 

(a)            Fully understands and voluntarily accepts the terms, meaning, and significance of this Second Amendment;

 

(b)            Has had ample time to obtain all of the legal advice that the Party deems necessary; and

 

(c)            Has had ample time to review this Second Amendment.

 

15.            Execution. This Second Amendment may be executed in multiple counterparts, all of which shall constitute one and the same Second Amendment. Delivery of an executed counterpart of this Second Amendment by email or by electronic means (e.g., DocuSign) shall be as effective as delivery of a manually executed counterpart of this Second Amendment. This Second Amendment may be executed by a Party’s signature transmitted by email, and copies of this Second Amendment executed and delivered by means of signatures sent by email or electronic means shall have the same force and effect as copies executed and delivered with original signatures.

 

16.            Cooperation. The Parties to this Second Amendment will cooperate in all manners necessary to effectuate the terms of this Second Amendment including, but not limited to, executing all necessary documents.

 

17.            Interpretation. No provision of this Second Amendment is to be interpreted for or against any Party because that Party, or that Party’s representative, drafted such provision.

 

The remainder of this page is intentionally left blank. Signature page follows.

 

 Page 5Second Amendment to 200 Pine Street Office Lease for Jaguar Health, Inc.

 

 

LANDLORD   TENANT
     
M&E LLC,   Jaguar Health, Inc.
a California limited liability company   A Delaware corporation
     
/s/ Caroline Sze   /s/ Lisa Conte
By: Caroline Sze   By: Lisa Conte
Its: Manager   Its: Chief Executive Officer

 

Signature PageSecond Amendment to 200 Pine Street Office Lease for Jaguar Health, Inc.

 

EX-101.SCH 4 jagx-20231025.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 jagx-20231025_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 jagx-20231025_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 25, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 25, 2023
Entity File Number 001-36714
Entity Registrant Name JAGUAR HEALTH, INC.
Entity Central Index Key 0001585608
Entity Tax Identification Number 46-2956775
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 200 Pine Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 415
Local Phone Number 371-8300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol JAGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2330328d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001585608 2023-10-25 2023-10-25 iso4217:USD shares iso4217:USD shares false 0001585608 8-K 2023-10-25 JAGUAR HEALTH, INC. DE 001-36714 46-2956775 200 Pine Street Suite 400 San Francisco CA 94104 415 371-8300 false false false false false Common Stock, Par Value $0.0001 Per Share JAGX NASDAQ EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jaguaranimalhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports jagx-20231025.xsd jagx-20231025_lab.xml jagx-20231025_pre.xml tm2330328d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330328d1_8k.htm": { "nsprefix": "jagx", "nsuri": "http://jaguaranimalhealth.com/20231025", "dts": { "schema": { "local": [ "jagx-20231025.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "jagx-20231025_lab.xml" ] }, "presentationLink": { "local": [ "jagx-20231025_pre.xml" ] }, "inline": { "local": [ "tm2330328d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://jaguaranimalhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330328d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330328d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-122909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-122909-xbrl.zip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end